非小细胞肺癌患者外周血中EGFR基因突变与埃克替尼治疗效果的相关性

目的 探讨非小细胞肺癌（NSCLC）患者外周血液中表皮生长因子受体（EGFR）基因突变与埃克替尼治疗效果的相关性。方法 选取洛阳市第三人民医院自2014年2月-2018年2月收治的101例NSCLC患者作为实验对象，采用RT-PCR技术检测外周血液中EGFR基因突变情况，依据测定结果分为基因突变组和野生型组，均采用埃克替尼治疗分析其治疗效果；选取同期做健康体检的患者50例作为对照组，比较NSCLC患者与健康人外周血液中EGFR突变差异。结果 50例健康人外周血液检测EGFR基因突变率为0，NSCLC患者中EGFR基因突变率为41.58%（42例），EGFR野生型组患者31.68%（32例），EGFR基因未突变者27例。基因突变组患者疾病控制率为85.71%，治疗有效率为64.29%；野生型组疾病控制率为59.38%，总有效率仅为12.5%，数据差异有统计学意义（P<0.05）。随访6个月内两组患者生存率差异无统计学意义，随访1、2年间EGFR基因突变组的生存率均远高于野生型组，数据差异有统计学意义（P<0.05）。结论 NSCLC患者外周血中EGFR基因突变患者行埃克替尼治疗效果更高，因此在晚期的NSCLC患者治疗中可以通过测定是否EGFR基因突变来指导靶向药物治疗。

Correlation between EGFR gene mutation in peripheral blood of patients with NSCLC and efficacy of Icotinib

Objective To investigate the relationship between the mutation of epidermal growth factor receptor (EGFR) gene in peripheral blood of patients with non-small cell lung cancer (NSCLC) and the therapeutic effect of Icotinib. Methods 101 cases of NSCLC patients admitted in our hospital from February 2014-2018 February were selected as experimental subjects. RT-PCR technique was used to detect the mutation of EGFR gene in the peripheral blood, and the results were divided into gene mutation group and wild type group according to the results. 50 patients with physical examination were used as control group. The difference of EGFR mutation in peripheral blood between NSCLC patients and healthy persons was compared. Results The mutation rate of EGFR gene was 0 in 50 healthy people. The mutation rate of EGFR gene in NSCLC patients was 41.58% (42 cases), 31.68% (32 cases) in EGFR wild type group and 27 cases of EGFR gene without mutation. The rate of disease control in the gene mutation group was 85.71%, the effective rate was 64.29%, the disease control rate of the wild type group was 59.38%, the total effective rate was only 12.5%, the difference of the data was statistically significant (P<0.05). The survival rate of the two groups in the two groups was not statistically significant during the follow-up period of six months, and the survival rate of the EGFR gene mutation group was followed up for one years and two years. The difference was statistically significant (P<0.05). Conclusion the effect of EGFR gene mutation in peripheral blood of NSCLC patients is more effective, so the targeted drug therapy can be guided by measuring the mutation of EGFR gene in the treatment of advanced NSCLC patients.